Extended indication Capivasertib is indicated in combination with abiraterone as treatment for patients with de novo met
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information